Gilead Sciences (GILD) Misses Q3 EPS by 8c, Revises 2014 Guidance
Get Alerts GILD Hot Sheet
Price: $73.25 +0.33%
Revenue Growth %: -0.5%
Financial Fact:
Shares used in per share calculation - basic: 1.32B
Today's EPS Names:
SHIM, KOD, HEWA, More
Revenue Growth %: -0.5%
Financial Fact:
Shares used in per share calculation - basic: 1.32B
Today's EPS Names:
SHIM, KOD, HEWA, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q3 EPS of $1.84, $0.08 worse than the analyst estimate of $1.92. Revenue for the quarter came in at $6.04 billion versus the consensus estimate of $5.99 billion.
Revised 2014 Full Year Guidance
Gilead updated its full year 2014 guidance, which it initially provided on February 4, 2014, updated on July 23, 2014, and further revised on October 28, 2014:
(In millions, except percentages and per share amounts) | Initially ProvidedFebruary 4, 2014;Reiterated April 22,2014 | UpdatedJuly 23, 2014 | Provided onOctober 28, 2014 | |||
Net Product Sales | $11,300 - $11,500 | $21,000 - $23,000 | $22,000 - $23,000 | |||
Non-GAAP* | ||||||
Product Gross Margin | 75% - 77% | 85% - 88% | 86% - 88% | |||
R&D | $2,200 - $2,300 | $2,300 - $2,400 | $2,300 - $2,400 | |||
SG&A | $2,100 - $2,200 | $2,300 - $2,400 | $2,700 - $2,800 ** | |||
Effective Tax Rate | 28% - 29% | 17.5% - 20.5% | 17.5% - 19.5% | |||
Diluted EPS Impact of Acquisition-Related, Restructuring and Stock-Based Compensation Expenses | $0.63 - $0.66 | $0.63 - $0.66 | $0.63 - $0.66 |
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- P3 Health Partners Inc. (PIII) Misses Q4 EPS by 14c, reaffirms guidance
- Walgreens Boots Alliance (WBA) tops Q2 expectations, narrows full-year profit forecast
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!